文献速递白血病

Lintuzumab-Ac225联合CLAG-M挽救治疗在复发/难治性急性髓系白血病中的1期研究

Phase 1 study of lintuzumab-Ac225 combined with CLAG-M salvage therapy in relapsed/refractory acute myeloid leukemia.
PubMed 文献 · Leukemia · 2025-02-15

这项1期研究评估了抗CD33抗体lintuzumab-Ac225在CLAG-M挽救治疗后用于复发/难治性急性髓系白血病(R/R AML)的安全性和疗效。采用3+3剂量递增设计,21例患者入组4个队列,另5例接受RP2D。MTD和RP2D为0.75 µCi/kg,常见3/4级不良事件为发热性中性粒细胞减少(65.4%)和白细胞减少(50%)。复合完全缓解率(CRc)总体为56.6%,TP53突变患者为50%,既往接受维奈克拉治疗患者为38.5%。

要点

  • Lintuzumab-Ac225联合CLAG-M在R/R AML中耐受良好,毒性可预期可控。
  • MTD和RP2D为0.75 µCi/kg,于CLAG-M(第1-6天)后7(+2)天输注。
  • CRc总体56.6%,TP53突变者50%,既往维奈克拉治疗者38.5%。

核心结论

  • Lintuzumab-Ac225联合CLAG-M在高危R/R AML患者中耐受良好,毒性可预期可控,并产生深度且有意义的缓解。

研究设计与样本

  • 1期研究,采用3+3剂量递增设计,21例患者序贯入组4个队列接受lintuzumab-Ac225(0.25-1.0 µCi/kg)于CLAG-M(第1-6天)后7(+2)天输注,另5例接受RP2D。
  • 主要目标为确定最大耐受剂量(MTD)、推荐2期剂量(RP2D)和安全性。
  • 可评估患者中86.7%具有高危疾病。

主要发现

  • MTD和RP2D为0.75 µCi/kg。
  • 常见3/4级不良事件为发热性中性粒细胞减少(65.4%)和白细胞减少(50%)。
  • 复合完全缓解率(CRc,CR/CRi)总体为56.6%,TP53突变患者为50%,既往维奈克拉治疗患者为38.5%。
  • 12例缓解者中8例达到可测量残留病(MRD)阴性。
  • 全部患者(n=26)中,估计2年总生存率为23.1%(95% CI,9.4-40.3),估计1年无进展生存率为30.8%(95% CI,14.6-48.5)。

关键数值与推荐

  • MTD和RP2D为0.75 µCi/kg。
  • CRc率:总体56.6%,TP53突变患者50%,既往维奈克拉治疗患者38.5%。
  • 12例缓解者中8例MRD阴性。
  • 全部患者(n=26)估计2年OS为23.1%(95% CI,9.4-40.3),估计1年PFS为30.8%(95% CI,14.6-48.5)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Lintuzumab-Ac255 is a humanized anti-CD33 antibody linked to Actinium-225 delivering high-energy alpha-particles to leukemia cells, inciting double-strand DNA breaks and cell death. This phase 1 study assessed the safety and efficacy of lintuzumab-Ac225 after CLAG-M salvage therapy in patients with relapsed/refractory acute myeloid leukemia (R/R AML). Primary objectives were determination of maximum tolerated dose (MTD), recommended phase 2 dose (RP2D), and safety. Using a 3 + 3 dose-escalation design, 21 patients were enrolled sequentially into 4 cohorts to receive a lintuzumab-Ac225 infusion (0.25-1.0 µCi/kg) 7 ( + 2) days after CLAG-M (days 1-6); 5 additional patients received the RP2D. Of evaluable patients, 86.7% had high-risk disease. The MTD and RP2D was 0.75 µCi/kg. Common grade 3/4 adverse events were febrile neutropenia (65.4%) and decreased white blood cells (50%). The composite complete remission (CRc) rates (CR/CRi) were 56.6% overall, 50% in patients with mutated TP53, and 38.5% in prior venetoclax-treated patients. Measurable residual disease (MRD)-negativity was achieved in 8 of 12 responders. Among all patients (n = 26), estimated 2-year OS was 23.1% (95% CI, 9.4-40.3) and estimated 1-year PFS was 30.8% (95% CI, 14.6-48.5). Lintuzumab-Ac225 plus CLAG-M was well tolerated with expected, manageable toxicities, while yielding deep and meaningful responses in high-risk R/R AML patients.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Abedin SM, Guru Murthy GS, Hamadani M, et al. Phase 1 study of lintuzumab-Ac225 combined with CLAG-M salvage therapy in relapsed/refractory acute myeloid leukemia. Leukemia. 2025. PMID: 39955432. doi:10.1038/s41375-025-02528-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。